Can you describe the BREAKWATER protocol for adult patients with untreated metastatic colorectal cancer harboring a BRAF V600E mutation, using encorafenib (Braftovi) and cetuximab (Erbitux)?

BREAKWATER Protocol: Encorafenib, Cetuximab, and mFOLFOX6

For adult patients with previously untreated BRAF V600E-mutated metastatic colorectal cancer, the BREAKWATER protocol combines encorafenib 300 mg orally once daily with cetuximab 500 mg/m² IV every 2 weeks plus mFOLFOX6 chemotherapy every 2 weeks, continuing until disease progression or unacceptable toxicity. 1

Regimen Components and Dosing

The BREAKWATER protocol consists of three agents administered concurrently: 1, 2

Encorafenib (Braftovi):

• 300 mg orally once daily 1
• Continue daily without interruption unless dose modification required 1

Cetuximab (Erbitux):

• 500 mg/m² IV infusion every 2 weeks 1
• No loading dose required in this regimen 1

mFOLFOX6 chemotherapy (every 2 weeks): 1

• Oxaliplatin 85 mg/m² IV
• Leucovorin 400 mg/m² IV
• 5-FU 400 mg/m² IV bolus
• 5-FU 2400 mg/m² continuous IV infusion over 46-48 hours

Patient Selection Criteria

Mandatory eligibility requirements: 1, 2

• BRAF V600E mutation-positive metastatic colorectal cancer confirmed by validated testing (Qiagen therascreen BRAF V600E RGQ PCR Kit) 1
• No prior systemic treatment in the metastatic setting 1
• Microsatellite stable (MSS) or proficient mismatch repair (pMMR) tumors, OR MSI-H/dMMR patients ineligible for immune checkpoint inhibitors 1
• RAS wild-type status (not RAS-mutated or unknown RAS status excluded) 1
• ECOG performance status 0-1 1

Key exclusions: 1

• Prior BRAF inhibitor or EGFR inhibitor therapy 1
• Active pancreatitis or leptomeningeal disease 1
• Chronic inflammatory bowel disease requiring medical intervention 1
• Clinically significant cardiovascular disease including myocardial infarction, acute coronary syndromes, NYHA Class ≥II heart failure, or prolonged QTcF interval (≥480 ms) 1

Efficacy Outcomes

The BREAKWATER trial demonstrated superior outcomes compared to standard chemotherapy with or without bevacizumab: 2

Progression-Free Survival:

• Median PFS: 12.8 months vs. 7.1 months (standard care) 2
• Hazard ratio: 0.53 (95% CI: 0.41-0.68; P<0.001) 2

Overall Survival (interim analysis):

• Median OS: 30.3 months vs. 15.1 months (standard care) 2
• Hazard ratio: 0.49 (95% CI: 0.38-0.63; P<0.001) 2

Objective Response Rate:

• ORR: 60.9% vs. 40.0% (standard care) 3
• Median duration of response: 13.9 months vs. 11.1 months 3

Safety Profile and Adverse Events

Common adverse reactions (≥25%): 1

• Peripheral neuropathy, nausea, fatigue, diarrhea, decreased appetite, rash, vomiting, hemorrhage, abdominal pain, arthralgia, pyrexia, and constipation 1

Serious adverse events occurred in 46% of patients: 1

• Most common (>3%): intestinal obstruction (4.7%), pyrexia (3.9%), sepsis (3.4%), abdominal pain (3.4%) 1
• Fatal events: intestinal obstruction (0.9%), large intestinal perforation and gastrointestinal perforation (0.4% each) 1

Dose modifications: 1

• Permanent discontinuation: 14% of patients (most common: increased lipase, sepsis) 1
• Dose interruptions: 68% of patients (most common ≥5%: neutropenia, anemia, pyrexia, COVID-19, diarrhea) 1
• Dose reductions: 25% of patients (most common ≥2%: fatigue, anemia, arthralgia, increased lipase, nausea, neurotoxicity, vomiting) 1

Laboratory abnormalities (Grade 3-4, ≥10%): 1

• Increased lipase, decreased neutrophil count, decreased hemoglobin, decreased white blood cell count, increased glucose 1

Treatment Duration and Monitoring

Continue treatment until: 1

• Disease progression 1
• Unacceptable toxicity 1
• Withdrawal of consent 1
• Lost to follow-up or death 1

Exposure data from trial: 1

• 73% of patients exposed for ≥6 months 1
• 48% of patients exposed for ≥1 year 1

Guideline Recommendations

ESMO guidelines (2023) recommend encorafenib-cetuximab as the best option for BRAF V600E-mutated, pre-treated mCRC patients in second line [I, A; ESMO-MCBS v1.1 score: 4; ESCAT: I-A]. 4 The BREAKWATER results have now established this combination with mFOLFOX6 as first-line therapy, representing a paradigm shift requiring early genomic testing to identify eligible patients. 5

ASCO guidelines (2023) address whether treatment with encorafenib plus cetuximab results in better outcomes compared with chemotherapy plus targeted therapy for previously treated BRAF V600E-mutant mCRC, 6 though these guidelines preceded the BREAKWATER first-line data.

Clinical Implementation Considerations

Critical pitfall: The tumor must be RAS wild-type; RAS-mutated tumors will not respond to anti-EGFR therapy regardless of BRAF status. 1 Early comprehensive genomic testing is essential to identify appropriate candidates. 5

Important distinction: This regimen uses encorafenib 300 mg daily (not the 450 mg dose used in melanoma with binimetinib). 1 The lower dose is specific to the colorectal cancer indication when combined with cetuximab and chemotherapy.